Abstract: The present invention concerns a nanotechnology-based delivery system of bergamot essential oil (BEO) that are ?-tocopheryl stearate-Solid Lipid Nanostructures (?-TFS-SLNs) loaded with bergamot essential oil without psoralens (BEO-BF). The present invention concerns also a method of preparation and uses of said ?-tocopheryl stearate-Solid Lipid Nanostructures (?-TFS-SLNs) loaded with bergamot essential oil (BEO-BF).

Abstract: An organic semiconductor material having high charge mobility characteristics and an organic semiconductor element is provided. The organic semiconductor material has rodlike low-molecular liquid crystallinity, including a skeleton structure comprising L 6 ? electron aromatic rings, M 10 ? electron aromatic rings, and N 14? electron aromatic rings, wherein L, M, and N are each an integer of 0 (zero) to 4 and L+M+N=1 to 4; and a terminal structure attached to both ends of the skeleton structure. The terminal structure can develop liquid crystallinity. The phase angle ? of impedance of the organic semiconductor material is ?80°????90° as determined in the measurement of impedance in a frequency f range of 100 Hz?f?1 MHz in such a state that the organic semiconductor material in an isotropic phase state is held between a pair of opposed substrates with an interelectrode spacing of 9 ?m.

Abstract: A pharmaceutical composition comprising a peptide derivative or its pharmaceutical equivalent salt having a general formula, R1N?C(R2)-AA1-AA2-AA3-AA4-Y, in which R1 is such as a hydrogen, R2 is such as a methyl group, Y is such as a methylamino group, AA1 is such as a tyrosine group, AA2 is such as a D-arginine group, AA3 is such as a phenylalanine group, and AA4 is such as a N-methyllysine group has analgesic activity against a variety of pains on both subcutaneous and oral administration.

Abstract: Disclosed are an organic semiconductor material having high charge mobility characteristics and an organic semiconductor element. The organic semiconductor material has rodlike low-molecular liquid crystallinity, comprising: a skeleton structure comprising L 6 &pgr; electron aromatic rings, M 10 &pgr; electron aromatic rings, and N 14 &pgr; electron aromatic rings, wherein L, M, and N are each an integer of 0 (zero) to 4 and L+M+N=1 to 4; and a terminal structure attached to both ends of the skeleton structure. The terminal structure can develop liquid crystallinity. The phase angle &thgr; of impedance of the organic semiconductor material is −80°≦&thgr;≦−90° as determined in the measurement of impedance in a frequency f range of 100 Hz≦f≦1 MHz in such a state that the organic semiconductor material in an isotropic phase state is held between a pair of opposed substrates with an interelectrode spacing of 9 &mgr;m.

Abstract: An analgesic agent is provided which has analgesic action and anti-inflammatory action without significant side effects found in conventional analgesics.

Abstract: An analgesic agent is provided which has analgesic action and anti-inflammatory action without significant side effects found in conventional analgesics.

Abstract: A peptide derivative having analgesic activity represented by the following Formula I: 1

Abstract: Compounds represented by the following general formula and salts thereof; Y-L-Tyr-Q-NR1—CH(R2)—CO—X, wherein R1 represents hydrogen or C1-6 alkyl; R2 represents optionally substituted benzyl; Q represents D- or L-Arg; Y represents two hydrogen atoms of N-terminal amino group of L-Tyr, or one or two functional groups substituting for the hydrogen atoms, for example, a C1-6 alkyl optionally having amino or carboxy; and X represents N-methyl-&bgr;-alanine and other. The compounds have analgesic effect and can be used for the treatment of cancer pain or the like.

Abstract: A peptide derivative having analgesic activity represented by the following Formula I: ##STR1## wherein Q represents D-Arg or L-Arg; and X represents for example NR.sup.6 --CHR.sup.7 R.sup.8. Typical compounds include H.sub.2 NC(NH)-Tyr-D-Arg-Phe-NHCH.sub.2 CH.sub.2 COOH and H.sub.2 NC(NH)-Tyr-D-Arg-Phe-NHCH.sub.2 CH.sub.2 CONH.sub.2.